Long-term safety of tiotropium/olodaterol Respimat^® in patients with moderate-to-very severe COPD and renal impairment in the TONADO^® studies

References

• AdeloyeDChuaSLeeCGlobal and regional estimates of COPD prevalence: systematic review and meta-analysisJ Glob Health20155202041526755942
   PubMed Web of Science ®Google Scholar
• World Health OrganizationChronic Respiratory Diseases Available from: http://www.who.int/respiratory/copd/burden/en/Accessed June 8, 2017
   Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2016 Report Available from: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/Accessed April 27, 2016
   Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• KunzCLuedtkeDUnseldAPharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal functionInt J Chron Obstruct Pulmon Dis20161158559527051282
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmaceuticals ISpiriva^® Respimat^® (tiotropium bromide) inhalation spray, for oral inhalation Available from: http://docs.boehringer-ingelheim.com/Prescribing%20.Information/PIs/Spiriva%20Respimat/spirivarespimat.pdfAccessed February 12, 2017
   Google Scholar
• Boehringer Ingelheim International GmbHSpiolto Respimat 2.5 microgram/2.5 microgram, inhalation solution. Summary of Product Characteristics, labelling and package leaflet 2015 Available from: http://mri.medagencies.org/download/NL_H_3157_001_FinalPI.pdfAccessed March 1, 2016
   Google Scholar
• Vande GriendJPLinneburSAInhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasiaAnn Pharmacother20124691245124922851743
   PubMed Web of Science ®Google Scholar
• AfonsoASVerhammeKMStrickerBHSturkenboomMCBrusselleGGInhaled anticholinergic drugs and risk of acute urinary retentionBJU Int201110781265127220880196
   PubMed Web of Science ®Google Scholar
• StephensonASeitzDBellCMInhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based studyArch Intern Med20111711091492021606096
   PubMedGoogle Scholar
• AfonsoASVerhammeKMSturkenboomMCBrusselleGGCOPD in the general population: prevalence, incidence and survivalRespir Med2011105121872188421852081
   PubMed Web of Science ®Google Scholar
• MiravitllesMPriceDRabeKFSchmidtHMetzdorfNCelliBComorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20151054956425834416
   PubMed Web of Science ®Google Scholar
• FreemanDLeeAPriceDEfficacy and safety of tiotropium in COPD patients in primary care–the SPiRiva Usual CarE (SPRUCE) studyRespir Res200784517605774
   PubMed Web of Science ®Google Scholar
• HalpinDMDahlRHallmannCMuellerATashkinDTiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysisInt J Chron Obstruct Pulmon Dis20151023925925709423
   PubMed Web of Science ®Google Scholar
• FoodUSDrug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function–Study Design, Data Analysis, and Impact on Dosing and Labeling Available from: https://www.fda.gov/downloads/drugs/guidances/ucm204959.pdfAccessed June 7, 2017
   Google Scholar
• CasarosaPBouyssouTGermeyerSSchnappAGantnerFPieperMPreclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugsJ Pharmacol Exp Ther2009330266066819478135
   PubMed Web of Science ®Google Scholar
• HohlfeldJMSharmaAvan NoordJAPharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary diseaseJ Clin Pharmacol201454440541424165906
   PubMed Web of Science ®Google Scholar
• CasarosaPKollakIKiechleTFunctional and biochemical rationales for the 24-hour-long duration of action of olodaterolJ Pharmacol Exp Ther2011337360060921357659
   PubMed Web of Science ®Google Scholar
• AalbersRMaleki-YazdiMRHamiltonARandomized, double-blind, dose-finding study for tiotropium when added to olodaterol, administered via the Respimat® inhaler in patients with chronic obstructive pulmonary diseaseAdv Ther201532980982226404912
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRBeckEHamiltonALKorduckiLKokerPFogartyCA randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting beta2-agonist, for 4 weeks in patients with chronic obstructive pulmonary diseaseRespir Med2015109559660525829298
   PubMed Web of Science ®Google Scholar
• CaillaudDLe MerreCMartinatYAguilaniuBPaviaDA dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patientsInt J Chron Obstruct Pulmon Dis20072455956518268929
   PubMedGoogle Scholar
• AstraZeneca UK LimitedDuaklir Genuair 340 micrograms/12 micrograms inhalation powder. Summary of Product Characteristics Available from: https://www.medicines.org.uk/emc/medicine/29652Accessed July 17, 2017
   Google Scholar
• FuhrRLeselbaumAAubetsJPharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: a phase 1, open-label, single-dose studyClin Pharmacol Drug Dev20165210911727138024
   PubMed Web of Science ®Google Scholar
• TurckDWeberWSigmundRPharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairmentJ Clin Pharmacol200444216317214747425
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals UK LtdUltibro^® Breezhaler 85 micrograms/43 micrograms, inhalation powder hard capsules. Summary of Product Characteristics Available from: https://www.medicines.org.uk/emc/medicine/29533Accessed July 17, 2017
   Google Scholar
• SchmidKPascualSGilEGOrtizSJansatJMPharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trialClin Ther201032101798181221194604
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline UKRelvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed. Summary of Product Characteristics Available from: https://hcp.gsk.co.uk/products/relvar.htmlAccessed July 17, 2017
   Google Scholar
• VerhammeKMvan BlijderveenNSturkenboomMCTiotropium and the risk of death in COPDN Engl J Med2014370548148224476443
   PubMed Web of Science ®Google Scholar
• TashkinDMetzdorfNHallmannCKönen-BergmannMKupasKDahlRSafety of tiotropium in renally impaired patientsEur Respir J201444P923
   Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDTiotropium Respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
   PubMed Web of Science ®Google Scholar
• TashkinDPLeimerIMetzdorfNDecramerMCardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trialRespir Res20151616526031308
   PubMed Web of Science ®Google Scholar
• FergusonGTKarpelJPClerisme-BeatyEGronkeLVossFBuhlREfficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by ageInt J Chron Obstruct Pulmon Dis2016112701271027843306
   PubMed Web of Science ®Google Scholar
• BuhlRMagderSBothnerULong-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary diseaseRespir Med2017122586627993292
   PubMed Web of Science ®Google Scholar
• AlaghaKPalotASofalviTLong-acting muscarinic receptor antagonists for the treatment of chronic airway diseasesTher Adv Chronic Dis201452859824587893
   PubMedGoogle Scholar
• MintzerJBurnsAAnticholinergic side-effects of drugs in elderly peopleJ R Soc Med200093945746211089480
   PubMed Web of Science ®Google Scholar
• CohenENardiYKrauseIA longitudinal assessment of the natural rate of decline in renal function with ageJ Nephrol201427663564124643437
   PubMed Web of Science ®Google Scholar
• BabaMShimboTHorioMLongitudinal study of the decline in renal function in healthy subjectsPLoS One2015106e012903626061083
   PubMed Web of Science ®Google Scholar
• LindemanRDTobinJShockNWLongitudinal studies on the rate of decline in renal function with ageJ Am Geriatr Soc19853342782853989190
   PubMed Web of Science ®Google Scholar
• CockcroftDWGaultMHPrediction of creatinine clearance from serum creatinineNephron197616131411244564
   PubMed Web of Science ®Google Scholar
• StevensLANolinTDRichardsonMMComparison of drug dosing recommendations based on measured GFR and kidney function estimating equationsAm J Kidney Dis2009541334219446939
   PubMed Web of Science ®Google Scholar
• VerhaveJCFeslerPRibsteinJdu CailarGMimranAEstimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass indexAm J Kidney Dis200546223324116112041
   PubMed Web of Science ®Google Scholar
• PedoneCCorsonelloAIncalziRAGIFA InvestigatorsEstimating renal function in older people: a comparison of three formulasAge Ageing200635212112616495291
   PubMed Web of Science ®Google Scholar